WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 11, 269-281. Review Article ISSN 2277–7105

ROLE OF COMMUNITY PHARMACISTS IN ADR MONITORING: A COMPREHENSIVE REVIEW

Anju K. R.*[1], Shruti Palaskar[2], Nikita Yadav[3], Bhavesh Choudhary[4], Sanjiv Vishwakarm[5], Shrutika Patil[6]

TMV's Lokmanya Tilak Institute of Pharmacy, Kharghar, 410210.

Article Received on 30 April 2026,
Article Revised on 20 May 2026,
Article Published on 01 June 2026,

https://doi.org/10.5281/zenodo.20438670

***Corresponding Author**
Anju K. R.
TMV's Lokmanya Tilak Institute of Pharmacy, Kharghar, 410210.

How to cite this Article: Anju K. R.*[1], Shruti Palaskar[2], Nikita Yadav[3], Bhavesh Choudhary[4], Sanjiv Vishwakarm[5], Shrutika Patil[6] (2026). Role Of Community Pharmacists In Adr Monitoring: A Comprehensive Review. World Journal of Pharmaceutical Research, 15(11), 296–281.

ABSTRACT

Adverse drug reactions (ADRs) are a significant public health concern contributing to morbidity, mortality, and increased healthcare costs worldwide. Pharmacovigilance systems aim to detect, assess, understand, and prevent ADRs associated with medicines. Community pharmacists are among the most accessible healthcare professionals and play an essential role in identifying, documenting, and reporting ADRs. This review highlights the role of community pharmacists in ADR monitoring, reporting systems, challenges faced in reporting, and strategies to strengthen pharmacist participation in pharmacovigilance programs. The integration of pharmacists in ADR monitoring systems can significantly enhance medication safety and improve patient outcomes.

KEYWORDS: Adverse Drug Reactions, Pharmacovigilance, Community Pharmacist, Drug Safety, ADR Reporting.

1. INTRODUCTION

Adverse Drug Reactions (ADRs) are unintended and harmful responses to medicines occurring at normal therapeutic doses. ADRs contribute to increased hospitalization rates and healthcare costs globally. Pharmacovigilance is the science related to detecting, assessing, understanding, and preventing adverse effects or drug-related problems. Community pharmacists are uniquely positioned to contribute to ADR monitoring due to their frequent interaction with patients and their expertise in pharmacotherapy.[1]

Adverse drug reactions (ADRs) significantly impact the healthcare systems in terms of morbidity, mortality, and financial burden that might be associated with treating patients with ADRs. the monitoring of ADRs is considered the fundamental concept of pharmacovigilance, which is defined as the "pharmaceutical science and activities relating to the detection, assessment, understanding, and prevention of adverse events or any other drug-related problems". Pharmacovigilance is a continuous process that is usually started from the initial stages of the drug development process to clinical trials and post-marketing surveillance activities. In 2009, Saudi Arabia established the National Pharmacovigilance.[2]

Center (NPC) under the umbrella of the Saudi Food and Drug Administration (SFDA), which later became a full member of the WHO's Uppsala Monitoring Center The NPC-SFDA is responsible for collecting the spontaneous reporting forms via the Saudi Vigilance System (SVS). the system's primary goal is to report and monitor the safety and effectiveness of chemical and biological medications, medical devices, food and herbal supplements, and cosmetics products. the SFDA accepted.[2]

1.1 Definition of ADR

An Adverse Drug Reaction (ADR) refers to any harmful, unintended, or undesirable response that occurs after the administration of a drug at normal therapeutic doses used for prevention, diagnosis, or treatment of disease.[1] According to the World Health Organization, an ADR is defined as a response to a drug which is noxious and unintended and occurs at doses normally used in humans for prophylaxis, diagnosis, therapy of disease, or modification of physiological function. ADRs are a major concern in healthcare because they can lead to patient morbidity, mortality, prolonged hospitalization, and increased healthcare costs. Studies have reported that approximately 5–10% of hospital admissions are related to adverse drug reactions, highlighting the importance of monitoring drug safety in clinical practice.[3]

1.2 Definition of ADR Monitoring

ADR monitoring is the continuous process of detecting, collecting, assessing, and reporting adverse drug reactions after drug administration to ensure the safety and effective use of medicines. It is an important activity of pharmacovigilance aimed at identifying and preventing harmful drug effects.[4]

Through ADR monitoring programs, healthcare professionals such as pharmacists, physicians, and nurses report suspected adverse reactions to national or international drug safety centers. These reports help regulatory authorities evaluate the safety profile of medicines and take appropriate actions such as updating drug information, issuing warnings, or withdrawing unsafe drugs from the market. Continuous ADR monitoring therefore plays a crucial role in improving patient safety, optimizing drug therapy, and promoting rational use of medicines in healthcare systems.[4][5]

2. In Pharmacovigilance ADR Monitoring

Pharmacovigilance systems operate globally to monitor medicine safety after drugs are marketed. Healthcare professionals including physicians, pharmacists, and nurses report suspected ADRs to national monitoring centers. These reports are analyzed to identify potential safety signals and improve drug safety. Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. This definition is provided by the World Health Organization and is widely accepted in research and clinical practice.[2][3]

Pharmacovigilance plays an essential role in modern healthcare by ensuring that medicines remain safe and effective throughout their lifecycle. While clinical trials establish the safety of drugs before approval, some adverse effects may only become apparent when drugs are used in a large population. Therefore, continuous monitoring through pharmacovigilance systems is necessary to detect Adverse Drug Reactions (ADRs) early and reduce risks to patients.[2]

The concept of pharmacovigilance includes several important processes such as ADR detection, causality assessment, risk evaluation, and prevention strategies. It also involves collecting data from healthcare professionals, especially community pharmacists, hospitals, and patients, and analyzing this data to identify safety signals. These signals may lead to regulatory actions such as label changes, warnings, or withdrawal of unsafe drugs.[3]

In India, pharmacovigilance is implemented through the Pharmacovigilance Programmer of India, coordinated by the Indian Pharmacopoeia Commission, which collects and evaluates ADR reports from across the country. Community pharmacists play a key role by identifying and reporting ADRs and educating patients about safe drug use.[4]

1.Detection of Adverse Drug Reactions (ADRs): Systematic identification and recognition of suspected adverse events arising from medicinal product exposure in clinical or real-world settings.[5]

2. Causality Assessment: Critical evaluation of the likelihood of a causal association between a suspected drug and the observed adverse event using standardized criteria.[6]

3. Data Analysis and Signal Detection: Aggregation and statistical interpretation of pharmacovigilance data to identify safety signals, trends, and potential risk factors.[7]

4. Risk Minimization and Prevention: Implementation of regulatory and clinical interventions, including label modifications and risk communication, to mitigate drug-related hazards.[8]

5. Reporting and Documentation: Structured collection, documentation, and submission of ADR reports to national pharmacovigilance systems such as the Pharmacovigilance Programmer of India for ongoing surveillance.[7]

3. Role of Community Pharmacists

Community pharmacists play multiple roles including ADR detection, reporting, documentation, patient counselling, and prevention of medication-related problems. Their direct contact with patients allows them to identify adverse reactions early and guide patients toward safe medication practices.[9]

Community pharmacists play a significant role in the detection, prevention, and reporting of Adverse Drug Reactions (ADRs) in the healthcare system. They are often the first healthcare professionals to interact with patients during the dispensing of medicines and therefore have an important responsibility in ensuring drug safety. Pharmacists can identify possible ADRs by reviewing prescriptions, evaluating patient medication history, and observing symptoms reported by patients during follow-up visits.[8][9]

One of the major roles of community pharmacists is patient counselling. They educate patients about the correct use of medications, possible side effects, and precautions to reduce the risk of adverse drug reactions. By providing proper guidance, pharmacists help patients recognize early symptoms of ADRs and encourage them to seek medical attention if necessary.[10]

Community pharmacists also contribute to ADR reporting systems by documenting and reporting suspected adverse drug reactions to pharmacovigilance centres. In many countries,

these reports are submitted to national drug safety programs coordinated by organizations such as the World Health Organization and national pharmacovigilance centres. These reports help regulatory authorities evaluate the safety profile of medicines and take necessary regulatory actions.[11]

In addition, community pharmacists assist in monitoring drug therapy, especially in patients with chronic diseases who use multiple medications. They check for drug–drug interactions, inappropriate dosing, and medication errors that may lead to adverse reactions. By maintaining patient medication records and conducting regular follow-ups, pharmacists can identify and prevent potential ADRs.[12]

4. Methods of ADR Monitoring

ADR monitoring can be conducted through spontaneous reporting systems, cohort studies, case-control studies, and prescription event monitoring. Spontaneous reporting remains the most widely used method in pharmacovigilance systems worldwide.[13]

1. Spontaneous Reporting System (SRS)

This is the most common method of ADR monitoring. Healthcare professionals such as doctors, nurses, and pharmacists voluntarily report suspected adverse drug reactions to national pharmacovigilance centres. These reports help detect new or rare ADRs and improve drug safety.[14]

2. Cohort Event Monitoring (CEM)

In this method, a group of patients receiving a particular drug is followed over a period of time to observe and record any adverse drug reactions. It helps identify the frequency and pattern of ADRs associated with a specific medicine.[13][14]

3. Case-Control Studies

This observational method compares patients who experienced an adverse drug reaction (cases) with those who did not (controls). It helps determine whether a particular drug is associated with a specific adverse reaction.[15]

4. Intensive Monitoring

This method involves continuous and detailed monitoring of patients in hospitals or clinics to detect adverse reactions. It is often conducted by trained healthcare professionals who record all drug-related events.[14][15]

5. Prescription Event Monitoring (PEM)

In this approach, data is collected from prescriptions and patient records to monitor the safety of medicines after they are marketed. It helps in identifying ADRs in large populations.[16]

6. Clinical Trials Monitoring

During clinical trials, drugs are carefully monitored for safety and adverse effects before they are approved for public use. Researchers record and analyse all adverse reactions during the study period.[17]

These ADR monitoring methods are used in pharmacovigilance programs coordinated by organizations such as the World Health Organization to ensure the safe and effective use of medicines.[18]

5. Challenges in ADR Reporting

Several barriers limit pharmacist participation in ADR reporting including lack of awareness about pharmacovigilance systems, insufficient training, heavy workload, lack of reporting forms, and fear of legal implications. Underreporting remains a major issue in ADR surveillance.[19]

1.Inadequate Awareness and Knowledge – Many healthcare professionals possess limited awareness regarding the importance of pharmacovigilance programs and ADR reporting mechanisms.[19]

2. Underreporting of ADRs – A significant proportion of adverse drug reactions remain unreported due to negligence, lack of initiative, or the assumption that the reaction is already well documented.[20]

3.Insufficient Training in Pharmacovigilance – Healthcare professionals often lack proper education and training related to ADR identification and reporting procedures.[20]

4.Time Constraints in Clinical Practice – Heavy workload and busy clinical schedules limit the time available for healthcare professionals to complete ADR reporting forms.[20]

5.Uncertainty in Establishing Causality – Determining whether a particular adverse event is directly related to a drug can be difficult, leading to hesitation in reporting.[21]

6.Fear of Legal or Professional Cones fences – Some healthcare providers avoid reporting ADRs due to concerns about legal liability or professional criticism.[21]

7.Complex and Lengthy Reporting Procedures – Complicated documentation processes and lengthy reporting forms may discourage healthcare professionals from reporting ADRs.[21]

8.Lack of Effective Communication – Poor coordination and communication among physicians, pharmacists, and nurses can lead to inadequate ADR documentation and reporting.[21]

9.Limited Patient Information – Incomplete medical records or insufficient drug history can make it challenging to accurately identify and report ADRs.[22]

10.Absence of Motivation or Incentives – Lack of recognition, feedback, or incentives may reduce the willingness of healthcare professionals to participate in ADR reporting systems.[23]

6. Strategies to Improve ADR Reporting

Training programs, digital reporting systems, pharmacist awareness campaigns, and integration of pharmacovigilance education into pharmacy curricula can significantly improve ADR reporting rates among pharmacists.[23]

1.Augmentation of Awareness Initiatives – Implementation of comprehensive awareness programs and educational campaigns can significantly improve the understanding of healthcare professionals regarding the importance and necessity of ADR reporting.[24]

2.Structured Pharmacovigilance Training Programs – Organizing regular workshops, seminars, and continuing professional education programs can enhance the competency of healthcare professionals in identifying, evaluating, and reporting ADRs.[24]

3.Simplification of Reporting Mechanisms – Development of concise, standardized, and user-friendly ADR reporting forms can reduce procedural complexity and encourage more frequent reporting.[24]

4.Integration into Routine Clinical Practice – Incorporating ADR monitoring and documentation as an integral component of routine clinical and pharmaceutical practice can improve the consistency and frequency of reporting.[24]

5.Adoption of Electronic Reporting Systems – Utilization of digital pharmacovigilance platforms and online reporting portals can streamline the reporting process and facilitate rapid data transmission.[24]

6.Promotion of Interdisciplinary Collaboration – Strengthening communication and cooperation among physicians, pharmacists, nurses, and other healthcare professionals can improve the identification and documentation of adverse drug reactions.[25]

7.Provision of Constructive Feedback – Offering systematic feedback and acknowledgement to healthcare professionals who report ADRs can serve as a motivational factor and promote sustained participation in pharmacovigilance activities.[25]

8.Incorporation into Academic Curriculum – Integrating pharmacovigilance and ADR reporting principles into medical, pharmacy, and nursing education can cultivate early awareness and professional responsibility among future healthcare practitioners.[25]

7. Impact on Patient Safety

Effective ADR monitoring helps identify harmful drug reactions early, prevent further complications, reduce hospital admissions, and improve overall medication safety.

Adverse Drug Reactions (ADRs) have a significant impact on patient safety and the overall quality of healthcare delivery. Unreported or poorly monitored ADRs can lead to increased morbidity, prolonged hospitalization, and, in severe cases, mortality. Effective identification and systematic reporting of ADRs contribute to the early detection of potential drug-related risks and enable regulatory authorities to implement appropriate safety measures. Furthermore, continuous pharmacovigilance activities facilitate the evaluation of the benefit–risk profile of medications, thereby promoting the rational and safe use of pharmaceutical products.[24][25]

Inadequate ADR monitoring and underreporting can compromise patient safety by delaying the recognition of harmful drug effects. This may result in repeated exposure of patients to potentially hazardous medications and the persistence of preventable adverse outcomes. Strengthening ADR reporting systems enhances clinical decision-making, improves therapeutic outcomes, and minimizes drug-related complications. Consequently, an efficient pharmacovigilance framework plays a crucial role in safeguarding public health and ensuring the safe administration of medicinal therapies.[26]

8. Future Perspectives

Future pharmacovigilance systems will increasingly use electronic health records, artificial intelligence, and digital reporting platforms. Community pharmacists will continue to play a vital role in these systems by ensuring safe medication use and reporting ADRs promptly.[27]

The future of Adverse Drug Reaction (ADR) monitoring is expected to evolve significantly with the advancement of pharmacovigilance systems and digital healthcare technologies. The integration of electronic health records, artificial intelligence, and big data analytics will facilitate the early detection and systematic evaluation of adverse drug reactions. These technological innovations can improve signal detection, enhance data accuracy, and enable

real-time monitoring of drug safety. Furthermore, global collaboration among regulatory authorities, healthcare institutions, and pharmaceutical industries will strengthen international pharmacovigilance networks and improve the sharing of drug safety information.[27]

In addition, increasing awareness and education among healthcare professionals and patients will play a vital role in improving ADR reporting in the future. The implementation of mobile applications and online reporting platforms will simplify the reporting process and encourage active participation from both healthcare providers and patients. Personalized medicine and pharmacogenomics may also help predict individual susceptibility to adverse drug reactions, thereby reducing drug-related risks. Consequently, the advancement of innovative pharmacovigilance strategies will enhance patient safety and ensure the safer utilization of therapeutic agents.[27]

CONCLUSION

Community pharmacists are essential contributors to pharmacovigilance systems. Their accessibility, knowledge of medicines, and frequent patient interaction make them key professionals in detecting and reporting adverse drug reactions. Strengthening training programs and improving reporting infrastructure can enhance their contribution to medication safety.

Effective monitoring and reporting of Adverse Drug Reactions (ADRs) are indispensable components of a robust pharmacovigilance system aimed at safeguarding patient safety and optimizing therapeutic outcomes. Strengthening awareness, improving reporting mechanisms, and fostering interdisciplinary collaboration among healthcare professionals can significantly mitigate the problem of underreporting. Moreover, the integration of advanced technologies and continuous professional education will enhance the efficiency of ADR surveillance systems. Therefore, a well-structured and proactive pharmacovigilance framework is essential for ensuring the safe, rational, and effective use of medicinal products in clinical practice.

REFERENCE

1. Selvam S, Karthik S, Sankaravadivel AR, Durai KS, Rajarathinam N, Raja S, Jothibabu I. Knowledge attitude and practice of pharmacovigilance among community pharmacy in India: a questionnaire study. International Journal of Basic & Clinical Pharmacology, 2024 Sep; 13(5): 636.

2. Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharmacy world & science, 2008 Oct; 30(5): 556-62.
3. Alshahrani S, Ali M, Alsreaya R, Najie M, Hijri A, Almalki A, Hassany E, Alhazmi A, Mirqami B, Tawhari F, Bajawi Y. Pharmacovigilance in Practice: Insights into Knowledge, Attitudes, and Practices of Pharmacists and Pharmacy Technicians in Saudi Arabia. Journal of Research in Pharmacy Practice, 2025 Apr 1; 14(2): 50-8.
4. Alwidyan T, Odeh M, Ibrahim AH, Harahsheh E, Banat A. Knowledge, attitude, and practice among community pharmacists toward adverse drug reaction reporting and pharmacovigilance: A nationwide survey. Exploratory Research in Clinical and Social Pharmacy, 2025 Jun 1; 18: 100578.
5. Craggy A, Small SS, Lau E, Rowe A, Lau A, Butcher K, Hohl CM. Sharing adverse drug event reports between hospitals and community pharmacists to inform re-dispensing: an analysis of reports and process outcomes. Drug Safety, 2023 Oct 2; 46(11): 1161.
6. Cai R, Liu M, Hu Y, Melton BL, Matheny ME, Xu H, Duan L, Waitman LR. Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports. Artificial intelligence in medicine, 2017 Feb 1; 76: 7-15.
7. Kumar D, Kaur A, Shruti 1, Kaur D. Artificial intelligence in pharmacovigilance. Current Computer Science, 2025 Jan; 4(1): E29503779340108.
8. Selvam S, Karthik S, Sankaravadivel AR, Durai KS, Rajarathinam N, Raja S, Jothibabu I. Knowledge attitude and practice of pharmacovigilance among community pharmacy in India: a questionnaire study. International Journal of Basic & Clinical Pharmacology, 2024 Sep; 13(5): 636.
9. Selvam S, Karthik S, Sankaravadivel AR, Durai KS, Rajarathinam N, Raja S, Jothibabu I. Knowledge attitude and practice of pharmacovigilance among community pharmacy in India: a questionnaire study. International Journal of Basic & Clinical Pharmacology, 2024 Sep; 13(5): 636.
10. Al Aqeel S, Abanmy N, AlShaya H, Almeshari A. Interventions for improving pharmacist-led patient counselling in the community setting: a systematic review. Systematic reviews, 2018 May 2; 7(1): 71.
11. Shareef J, Sridhar SB, Bhupathyraaj M, Shariff A, Thomas S. Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: A survey-based cross-sectional study. Therapeutic

1.Selvam S, Karthik S, Sankaravadivel AR, Durai KS, Rajarathinam N, Raja S, Jothibabu I. Knowledge attitude and practice of pharmacovigilance among community pharmacy in India: a questionnaire study. International Journal of Basic & Clinical Pharmacology, 2024 Sep; 13(5): 636.

12. Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharmacy world & science, 2008 Oct; 30(5): 556-62.
13. Alshahrani S, Ali M, Alsreaya R, Najie M, Hijri A, Almalki A, Hassany E, Alhazmi A, Mirqami B, Tawhari F, Bajawi Y. Pharmacovigilance in Practice: Insights into Knowledge, Attitudes, and Practices of Pharmacists and Pharmacy Technicians in Saudi Arabia. Journal of Research in Pharmacy Practice, 2025 Apr 1; 14(2): 50-8.
14. Alwidyan T, Odeh M, Ibrahim AH, Harahsheh E, Banat A. Knowledge, attitude, and practice among community pharmacists toward adverse drug reaction reporting and pharmacovigilance: A nationwide survey. Exploratory Research in Clinical and Social Pharmacy, 2025 Jun 1; 18: 100578.
15. Craggy A, Small SS, Lau E, Rowe A, Lau A, Butcher K, Hohl CM. Sharing adverse drug event reports between hospitals and community pharmacists to inform re-dispensing: an analysis of reports and process outcomes. Drug Safety, 2023 Oct 2; 46(11): 1161.
16. Cai R, Liu M, Hu Y, Melton BL, Matheny ME, Xu H, Duan L, Waitman LR. Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports. Artificial intelligence in medicine, 2017 Feb 1; 76: 7-15.
17. Kumar D, Kaur A, Shruti 1, Kaur D. Artificial intelligence in pharmacovigilance. Current Computer Science, 2025 Jan; 4(1): E29503779340108.
18. Selvam S, Karthik S, Sankaravadivel AR, Durai KS, Rajarathinam N, Raja S, Jothibabu I. Knowledge attitude and practice of pharmacovigilance among community pharmacy in India: a questionnaire study. International Journal of Basic & Clinical Pharmacology, 2024 Sep; 13(5): 636.
19. Selvam S, Karthik S, Sankaravadivel AR, Durai KS, Rajarathinam N, Raja S, Jothibabu I. Knowledge attitude and practice of pharmacovigilance among community pharmacy in India: a questionnaire study. International Journal of Basic & Clinical Pharmacology, 2024 Sep; 13(5): 636. advances in drug safety, 2024 Oct; 15: 20420986241285930.
20. Shareef J, Sridhar SB, Bhupathyraaj M, Shariff A, Thomas S. Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its

reporting in the United Arab Emirates: A survey-based cross-sectional study. Therapeutic advances in drug safety, 2024 Oct; 15: 20420986241285930.

21. Montané E, Sanz Y, Martin S, Pérez-Mañá C, Papaseit E, Hladun O, De la Rosa G, Farré M. Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital. Frontiers in pharmacology, 2024 Dec 5; 15: 1427772.
22. Patra V, Tekulapally K. Knowledge, attitude, and practices of pharmacovigilance among health-care professionals in a tertiary care teaching hospital in Telangana state. National Journal of Physiology, Pharmacy and Pharmacology, 2021 Jun 1; 11(6): 579
23. Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM. The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Safety, 2024 Jun; 47(6): 585-99.
24. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. Risk-treatment mismatch in the pharmacotherapy of heart failure. Jama, 2005 Sep 14; 294(10): 1240-7.
25. Hammad TA, Davis S, Afsar S. Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence. Frontiers in Drug Safety and Regulation, 2024 Aug 16; 4: 1445998.
26. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. World Health Organization; 2004.
27. Khabbaz HJ. Healthcare Professionals' Knowledge, Attitude and Perception toward Adverse Drug Reaction Reporting in Saudi Arabia: a Systematic Review. J Pharm Res Int, 2023 Nov 3; 35(28): 36-48.
28. Shareef J, Sridhar SB, Bhupathyraaj M, Shariff A, Thomas S. Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: A survey-based cross-sectional study. Therapeutic advances in drug safety, 2024 Oct; 15: 20420986241285930.
29. Perdigão M, Advinha AM, Lopes MJ, Martins SD. Empowering citizens to spontaneously report suspected adverse drug reaction: Systematic literature review of interventions and their impact. British Journal of Clinical Pharmacology, 2026 Feb 17.

30. SCHIAVO G, FORGERINI M, MASTROIANNI PC. Aplicação de ferramentas de rastreio de eventos adversos a medicamentos na gestão da assistência farmacêutica. Journal of Hospital Pharmacy and Health Services, 2025 Mar 31; 16(1): e1266-.
31. Saleem AH, Al-Qazaz HK, Allela OQ, Elkalmi RM. Knowledge, Attitude, and Practice of Pharmacovigilance and Adverse Drug Reactions Reporting Among Healthcare Providers in the Middle East: A Systematic Review. BioMed Visions Journal, 2026; 2(1): 1-9.
32. Alenzi KA, Alsuhaibani D, Batarfi B, Alshammari TM. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Frontiers in pharmacology, 2024 May 27; 15: 1364110.
33. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. Journal of Pharmacology and Pharmacotherapeutics, 2013 Dec; 4(1_suppl): S73-7.
34. Kumar D, Kaur A, Shruti 1, Kaur D. Artificial intelligence in pharmacovigilance. Current Computer Science, 2025 Jan; 4(1): E29503779340108.
35. Jose J, Cox AR, Bate A. Introduction to Drug Safety and Pharmacovigilance. InPrinciples and Practice of Pharmacovigilance and Drug Safety, 2024 Aug 6 (pp. 3-30). Cham: Springer International Publishing.